• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.

作者信息

Yang Xue, Huang Chuan, Chen Rongrong, Zhao Jun

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China.

Thoracic Surgery Ward (C05), Beijing Hospital, National Center of Gerontology, Beijing, China.

出版信息

Clin Lung Cancer. 2020 Jul;21(4):e258-e260. doi: 10.1016/j.cllc.2019.12.002. Epub 2020 Jan 23.

DOI:10.1016/j.cllc.2019.12.002
PMID:32146032
Abstract
摘要

相似文献

1
Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.在一名患有EGFR L718Q突变的非小细胞肺癌患者中使用阿法替尼解决对奥希替尼治疗的耐药性
Clin Lung Cancer. 2020 Jul;21(4):e258-e260. doi: 10.1016/j.cllc.2019.12.002. Epub 2020 Jan 23.
2
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.Sunvozertinib克服携带EGFR外显子18 DelE709_T710insD突变的肺腺癌对阿法替尼和奥希替尼的耐药性。
J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.
3
Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.一名对阿法替尼有反应的非小细胞肺癌患者出现获得性表皮生长因子受体（EGFR）L718V突变及T790M介导的奥希替尼耐药性丧失
J Thorac Oncol. 2019 Dec;14(12):e274-e275. doi: 10.1016/j.jtho.2019.07.018.
4
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.肺腺癌中一种新型获得性外显子 20 EGFR M766Q 突变介导奥希替尼耐药，但对奈拉替尼和波齐替尼敏感。
J Thorac Oncol. 2019 Nov;14(11):1982-1988. doi: 10.1016/j.jtho.2019.06.015. Epub 2019 Jun 27.
5
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.阿法替尼帮助克服 NSCLC 伴脑膜转移患者奥希替尼后继发性耐药，该患者存在获得性 EGFR L718Q 突变：一例报告。
BMC Cancer. 2019 Jul 17;19(1):702. doi: 10.1186/s12885-019-5915-7.
6
Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.达可替尼克服 EGFR L718Q 突变的晚期 NSCLC 患者对奥希替尼的获得性耐药：两例报告。
Medicine (Baltimore). 2024 Jul 12;103(28):e38789. doi: 10.1097/MD.0000000000038789.
7
Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.阿法替尼治疗奥希替尼获得性 EGFR L718V 突变介导耐药的肺腺癌患者的持久临床获益：病例报告及文献复习。
Ann Palliat Med. 2022 Mar;11(3):1126-1134. doi: 10.21037/apm-21-3731.
8
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance Mutations.一线奥希替尼耐药突变的药物敏感性和等位基因特异性。
Cancer Res. 2020 May 15;80(10):2017-2030. doi: 10.1158/0008-5472.CAN-19-3819. Epub 2020 Mar 19.
9
Mechanisms of acquired resistance to afatinib clarified with liquid biopsy.液体活检阐明了阿法替尼获得性耐药的机制。
PLoS One. 2018 Dec 14;13(12):e0209384. doi: 10.1371/journal.pone.0209384. eCollection 2018.
10
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.阿法替尼联合贝伐珠单抗治疗奥希替尼耐药肺腺癌伴 EGFR 外显子 18 突变（G719S）一例
Invest New Drugs. 2021 Feb;39(1):232-236. doi: 10.1007/s10637-020-00966-7. Epub 2020 Jun 18.

引用本文的文献

1
A rare epidermal growth factor receptor T790M/cis-C797S/L718Q compound mutation in a lung adenocarcinoma patient who did not derive any benefit from combination therapy with afatinib and bevacizumab.一名肺腺癌患者中罕见的表皮生长因子受体T790M/cis-C797S/L718Q复合突变，该患者未从阿法替尼和贝伐单抗联合治疗中获得任何益处。
SAGE Open Med Case Rep. 2025 Feb 17;13:2050313X251319381. doi: 10.1177/2050313X251319381. eCollection 2025.
2
Acquired multiple mutations‑mediated resistance to a third‑generation tyrosine kinase inhibitor in a patient with lung adenocarcinoma who responded to afatinib: A case report and literature review.一名对阿法替尼有反应的肺腺癌患者获得性多突变介导的对第三代酪氨酸激酶抑制剂的耐药性：病例报告及文献综述
Oncol Lett. 2024 Nov 27;29(2):81. doi: 10.3892/ol.2024.14827. eCollection 2025 Feb.
3
Characterization of Patients with Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.奥希替尼耐药突变L718Q或G724S出现后，携带突变阳性非小细胞肺癌患者的特征：法国一项多中心回顾性观察研究
Onco Targets Ther. 2024 May 29;17:439-448. doi: 10.2147/OTT.S448909. eCollection 2024.
4
Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report.序贯表皮生长因子受体酪氨酸激酶抑制剂诱导的寡转移非小细胞肺癌根治性手术：1 例报告。
Oncologist. 2024 Jun 3;29(6):543-545. doi: 10.1093/oncolo/oyad339.
5
Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment.表皮生长因子受体/人表皮生长因子受体 2-NAMPT 缀合物的合成及用于肿瘤治疗的生物学评价。
Mol Divers. 2024 Aug;28(4):2617-2636. doi: 10.1007/s11030-023-10701-y. Epub 2023 Jul 23.
6
[Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review].奥莫替尼联合贝伐单抗治疗初治原发性EGFR T790M突变晚期NSCLC：三例报告及文献复习
Zhongguo Fei Ai Za Zhi. 2023 Feb 20;26(2):158-164. doi: 10.3779/j.issn.1009-3419.2023.101.04.
7
Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With -Mutant NSCLC: A Case Report.在一名携带EGFR突变的非小细胞肺癌患者中使用吉非替尼通过T790M缺失和C797S获得克服对奥希替尼的耐药性：一例报告
JTO Clin Res Rep. 2022 Dec 28;4(2):100456. doi: 10.1016/j.jtocrr.2022.100456. eCollection 2023 Feb.
8
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。
J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.
9
Case Report: A patient with the rare third-generation TKI-resistant mutation L718Q who responded to afatinib plus cetuximab combination therapy.病例报告：一名患有罕见的第三代酪氨酸激酶抑制剂（TKI）耐药突变L718Q的患者对阿法替尼联合西妥昔单抗的联合治疗有反应。
Front Oncol. 2022 Oct 31;12:995624. doi: 10.3389/fonc.2022.995624. eCollection 2022.
10
"Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients.在高度选择的患者中通过酪氨酸激酶抑制剂与单克隆抗体联合治疗强化表皮生长因子受体（EGFR）阻断的“三明治”策略
Front Oncol. 2022 Jul 8;12:952939. doi: 10.3389/fonc.2022.952939. eCollection 2022.